1. Miettinen M. Diagnostic soft tissue pathology. Philadelphia: Churchill Livingstone; 2003.
2. Enzinger FM, Weiss, S.W., Goldblum J.R. Enzinger and Weiss's Soft Tissue Tumors. 4 ed. St. Louis: Mosby; 2001.
3. Fletcher DM, Unni, K.K., Mertens, F. World Health Organization
Calssification of Tumours. Pathology & Genetics Tumours of Soft Tissue and Bone. Lyon (Frankreich): International Agency for Research on Cancer Press;
2002.
4. Fletcher CD. Pleomorphic Malignant Fibrous Histiocytoma: Fact or Fiction? The American Journal of Surgical Pathology 1992;16(3):213-28.
5. Fletcher CDM. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathol 2006;48:3-12.
6. Antonescu CR. The role of genetic testing in sot tissue sarcoma.
Histopathol 2006;48:13-21.
7. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults:
state of the translational science. Clin Cancer Res 2003;9(6):1941-56.
8. Gutierrez JC, Perez EA, Franceschi D, Moffat FL, Jr., Livingstone AS, Koniaris LG. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007;141(1):105-14.
9. Engellau J, Bendahl, P., Persson, A., Domanski, H.A., Akerman, M., Gustafson, P., Alvegard, T.A., Nilbert, M., Rydholm A. Improved prognostic in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Human Pathology 2005;36:994-1002.
10. Kasper DL, Braunwald, E., Fauci, A.S., Hauser, S.L., Longo, D.L., Jameson J.L. Harrisons Innere Medezin. Berlin: ABW Wissenschaftsverlag;
2005.
11. Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005;65(2):167-78.
12. Zalcberg JR, Verweij, J., Casali, P.G., Le Cesne, A., Reichardt, P., Blay, J.Y., Schlemmer, M., Van Blabbeke, M., Brown, M., Judson, I.R. Outcome of patients with adavanced gastro-intestinal stromal tumours crossing over to a
daily imatinib dose of 800 mg after progression on 400 mg. Euroean Journal of Cancer 2005;41:1751-7.
13. Ray-Coquard I, Le Cesne, A., Michallet, V., Boukovinas, I., Ranchere, D., Thiesse, P., Baty, V., Blay, J.-Y. Tumeurs stromales du tractus digestif: actualités 2003. Bulletin du Cancer 2003;90(1):69-76.
14. Essat M, Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer;128(9):2202-14.
15. Robboy SJ, Bentley RC, Butnor K, Anderson MC. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000;108 Suppl 5:779-84.
16. Dal Cin P. Cytogenetics of Soft Tissue Tumours. Verh Dtsch Ges Path 1998;82:47-58.
17. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology 2006;48(1):97-105.
18. Fletcher CDM, Hamilton, S.R., Aaltonen, L.A. World Health Organization Classification of Tumours Pahtology & Genetics Tumours of the Digestive
System. Lyon (Frankreich): International Agency for Research on Cancer Press;
2000.
19. Böcker D, Heitz. Pathologie. München: Urban & Fischer; 2004.
20. Evans HL. Atypical Lipomatous Tumor, ist Variants, and ist Combined Forms. Am J Surg Pathol 2007;31(1):1-14.
21. Ganten R. Grundlagen der Molekularen Medizin. Berlin: Springer-Verlag;
2003.
22. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991;9(7):1283-97.
23. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993;17(1):263-5.
24. Kulozik AE, Hentze, M.W., Hagemeier, C., Bartram C.R. Molekulare Medizin: Grundlagen - Pathomechanismen - Klinik. Berlin: de Gruyter; 2000.
25. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138(3):863-70.
26. Mosselman S, Polman, J., Dijkema, R. ERbeta: identification and
characterization of a novel human estrogen receptor. FEBS Letters 1996;392:49-53.
27. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39(5):655-60.
28. Mutschler E, Geisslinger, G., Kroemer, H. K., Schäfer-Korting, M.
Mutschler Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie.
Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart; 2001.
29. Schwab M. "Oncogne amplification in solid tumors". Cancer Biology 1999;9:319-25.
30. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987;47(16):4355-60.
31. Ip M, Milholland RJ, Rosen F, Kim U. Mammary cancer: selective action of the estrogen receptor complex. Science 1979;203(4378):361-3.
32. Noble RL, Hochachka BC, King D. Spontaneous and estrogen-produced tumors in Nb rats and their behavior after transplantation. Cancer Res
1975;35(3):766-80.
33. Noble RL, Hoover L. A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. Cancer Res 1975;35(11 Pt 1):2935-41.
34. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007;99(5):350-6.
35. Harvey JM, Clark, G.M., Osborne, C.K. Allred, D.C.,. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol 1999;17(5):1474-81.
36. Andersen J, Poulsen HS. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989;64(9):1901-8.
37. Levine PH, Wei XJ, Gagner JP, Flax H, Mittal K, Blank SV. Pleomorphic liposarcoma of the uterus: case report and literature review. Int J Gynecol Pathol 2003;22(4):407-11.
38. Le Bouedec G, Auvray, H., Curé, H., de Latour, M., Penault-Llorca, F.,
Dauplat, J. Sarcome untérin survenant au cours d'une hormonothérapie par tamoxifène. À propos de deux cas. Rev Méd Interne 2001;22:881-5.
39. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20(11):2758-60.
40. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844-7.
41. Moch H, Kononen T, Kallioniemi OP, Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol
2001;8(1):14-20.
42. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10(7):657-62.
43. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003;2(12):962-72.
44. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res
1999;5(8):1966-75.
45. DAKO. ER/PR pharmDx Interpretation Manual. Glostrup (Dänemark):
DAKO.
46. Abbott x, Laboratories. 2006.
47. Pfleiderer A. BM, Martius G. Gynäkologie und Geburtshilfe. Stuttgart, New York: Thieme; 2002.
48. Schmidt-Matthiesen H, Hepp H. Gynäkologie und Geburtshilfe. Stuttgart, New York: Schattauer; 1998.
49. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K.
Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004;81(4):1062-6.
50. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14(5):465-71.
51. Gokaslan H, Turkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005;59(1):36-40.
52. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray
immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer
2004;101(6):1455-62.
53. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999;18(1):20-8.
54. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 1999;12(11):1001-9.
55. Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecologic oncology 2004;92(1):71-9.
56. Kayser K, Zink S, Schneider T, et al. Benign metastasizing leiomyoma of the uterus: documentation of clinical, immunohistochemical and
lectin-histochemical data of ten cases. Virchows Arch 2000;437(3):284-92.
57. Jautzke G, Muller-Ruchholtz E, Thalmann U. Immunohistological detection of estrogen and progesterone receptors in multiple and well
differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 1996;192(3):215-23.
58. Paal E, Miettinen M. Retroperitoneal leiomyomas: a clinicopathologic and immunohistochemical study of 56 cases with a comparison to retroperitoneal leiomyosarcomas. Am J Surg Pathol 2001;25(11):1355-63.
59. Patton KT, Cheng L, Papavero V, et al. Benign metastasizing leiomyoma:
clonality, telomere length and clinicopathologic analysis. Mod Pathol 2006;19(1):130-40.
60. Mittal K, Joutovsky A. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecologic oncology 2007;104(2):362-5.
61. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003;23(1B):729-32.
62. Weiss SW, Langloss JM, Shmookler BM, et al. Estrogen receptor protein in bone and soft tissue tumors. Lab Invest 1986;54(6):689-94.
63. Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK. Distribution of steroid hormone receptors in human soft tissue sarcomas. Surgery
1981;90(2):149-53.
64. Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine
leiomyosarcomas. A clinicopathologic study. Gynecologic oncology 2005;99(1):36-42.
65. Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 2004;12(4):338-41.
66. Li XQ, Hisaoka M, Hashimoto H. Expression of estrogen receptors alpha and beta in soft tissue sarcomas: Immunohistochemical and molecular analysis.
Pathol Int 2003;53(10):671-9.
67. Li B, Zhu L, Wang D. [A clinicopathological study of bizarre leiomyoma].
Zhonghua Bing Li Xue Za Zhi 2002;31(5):404-6.
68. Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK. The steroid hormone receptors in tumors of adipose tissue. J Surg Oncol 1985;28(2):87-9.
69. Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK. Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin.
Cancer Res 1980;40(3):861-5.
70. Ockner DM, Sayadi H, Swanson PE, Ritter JH, Wick MR. Genital
angiomyofibroblastoma. Comparison with aggressive angiomyxoma and other myxoid neoplasms of skin and soft tissue. Am J Clin Pathol 1997;107(1):36-44.
71. Brodsky SV, Gimenez, C., Ghosh, C. Melamed, M., Ramaswamy, G.
Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointstinal leiomyomas. int J Gastrointest Cancer 2006;37(4):129-32.
72. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol 1996;15(3):222-9.
73. Park WC, Jordan VC. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 2002;8(2):82-8.
74. Oliai BR, Tazelaar HD, Lloyd RV, Doria MI, Trastek VF. Leiomyosarcoma of the pulmonary veins. Am J Surg Pathol 1999;23(9):1082-8.
75. Esteban JM, Allen WM, Schaerf RH. Benign metastasizing leiomyoma of the uterus: histologic and immunohistochemical characterization of primary and metastatic lesions. Arch Pathol Lab Med 1999;123(10):960-2.
76. Schwartz SM, Weiss NS, Daling JR, et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996;77(4):717-24.
77. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Histopathology 2006;48(5):563-8.
78. Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP. Extragastrointestinal stromal tumors presenting as
vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol 2006;25(3):288-92.
79. Cantin J, McNeer, G. P. The Effect of Pregnancy on the clinical course of Sarcoma of the Soft Somatic Tissue. Surg Gynecol Obst 1967;125:28-32.
80. Wood PA, Hrushesky, W.J.M. Sex cycle modulates cancer growth. Breast Cancer Research and Treatment 2005;91:95-102.
81. Wade K, Quinn, M.A., Hammond, I., Williams, K., Cauchi, M. Uterine Sarcoma: Steroid Receptors and Response to Hormonal Therapy. Gynecologic Oncology 1990;39:364-7.
82. Sutton GP, Stehman, F.B., Michael, H., Young, P.C.M., Ehrlich, C.E.
Estrogen and Progesteron Receptors in Uterine Sacomas. Obstet Gynecol 1986;68:709-14.
83. Zacharin M, Waters, K., Chow, C.W., Crock, P., McKelvie, P. Recurrent Rhabdomyosarcoma After 25 Years: A Possible Association with Estrogen and Progesteron Therapy. Journal of Pediatric Hematoloy/ Oncology
1997;19(5):477-81.
84. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 1983;19(5):615-21.
85. Soper JT, McCarty, K.S., Hinshaw, W., Creasman, W.T., McCarty, K.S.
Sr., Clarke-Pearson, D.L. . Cytoplasmic estrogen and progesteron receptor
content of uterine sarcomas. Am J Obstet Gynecol 1984;150(342-348):342.
86. Mertens F, Strömberg, U., Mandahl, N., Dal Cin, P., De Wever, I.,
Fletcher, C.D.M., Mitelman, F., Rosai, J., Rydholm, A., Sciot, R., Tallini, G., Van den Berghe, H., Vanni, R., Willén, H. Prognostically Important Chromosomal Aberrations in Soft Tissue Sarcomas: A Report of the Chromosomes and Morphology (CHAMP) Study Group. Cancer Research 2002;62:3980-4.
87. Mertens F, Fletcher, C.D.M., Dal Cin, P., De Wever, I., Mandahl, N., Mitelman, F., Rosai, J., Rydholm, A., Sciot, R., Tallini, G., Van den Berghe, H., Vanni, R., Willén, H. Cytogenetic Analysis of 46 Pleomorphic Sot Tissue
Sarcomas and Correlation With Morphologic and Clinical Features: A Report of the CHAMP Study Group. Genes, Chromosomes & Cancer 1998;22:16-25.
88. Weng WH, Wejde, J., Ahlen, J., Pang, S.T., Lui, W.O., Larsson, C.
„Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative hybridization (CGH), and array CGH“. Cancer Genet Cytogenet 2004;150:27-32.
89. Rieker RJ, Joos S, Bartsch C, et al. Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer 2002;99(1):68-73.
90. Otano-Joos M, Mechtersheimer, G., Ohl, S., Wilgenbus, K.K., Scheurlen, W., Lehnert, T., Willeke, F., Otto, H.F., Lichter, P., Joos, S. Detection of
chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenetics and Cell Genetics 2000;90:86-92.
91. El-Rifai W, Sarlomo-Rikala, M., Knuutila, S., Miettinen, M. DNA Copy Number Changes in Deleloment and Progression in Leiomyosarcomas of Soft Tissue. American Journal of Pathology 1998;153(3):985-90.
92. Iliszko M, Mandahl, N., Mrozek, K., Denis, A., Pandis, N., Pejovic, T., Babinska, M., Nedoszytko, B., Debniak, J., Emerich, J., Hrabowska, M.,
Bloomfield, C.D., Limon, J. Cytogenetics of Uterine Sarcomas: Presentation of Eight New Cases and Review of the Literature. Gynecologic Oncology
1998;71:172-6.
93. Fritz B, Schubert F, Wrobel G, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002;62(11):2993-8.
94. Altungoz O, Meloni, A.M., Peier, A., Zalupski, M., Spanier, S., Brooks, J.S.J, Sandberg, A.A. „Deletion 6q in Three Cases of Mixed-type Liposarcoma in Addition to t(12;16)(q13;p11)“. Cancer Genet Cytogenet 1995;79:104-10.
95. Wa CV, DeVries S, Chen YY, Waldman FM, Hwang ES. Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. Mod Pathol 2005;18(4):591-7.
96. Rose C. Therapeutic Effect of Tamoxifen Related to Estrogen Receptor Level. Recent Results in Cancer Research 1980;71:134-41.
97. Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 2002;30(12):1365-72.
98. Al Kuraya K, Simon R, Sauter G. Tissue microarrays for high-throughput molecular pathology. Ann Saudi Med 2004;24(3):169-74.
99. Lotze MT, Wang E, Marincola FM, et al. Workshop on cancer biometrics:
identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother
2005;28(2):79-119.
100. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001;94(1):1-5.
101. Camp. Validation of tissue microarry technology in breast carcinoma. Lab Invest 2000;80:1943-9.
102. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol
2001;159(6):2249-56.
103. Sauter G, Mirlacher M. Tissue microarrays for predictive molecular pathology. J Clin Pathol 2002;55(8):575-6.
104. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194(3):349-57.
105. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.
J Pathol 2001;195(1):72-9.
106. West RB, van de Rijn, M. The role of microarray technologies in the study
of soft tissue tumours. Histopathol 2006;48:22-31.